PubMed · 360331
Clinical experiences with aclacinomycin-A.
Abstract
Aclacinomycin is a new anthracycline analog of adriamycin and daunomycin. Aclacinomycin contains three sugars. The drug has been studied in 22 cases in a phase 1 type of trial on a schedule 20 mg i.v. every other day up to a total of 300 mg. Toxicity has consisted of myelosuppression, nausea and vomiting, and transient hepatic disturbances. Evidence of clinical activity was observed in several cases including a case of breast cancer and gastric cancer. Although no full patial remissions were recorded, further study is continuing.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
H Furue, T Komita, I Nakao, I Furukawa, T Kanko, T Yokoyama. 1978. Clinical experiences with aclacinomycin-A.. https://doi.org/10.1007/978-3-642-81219-4_22
Cite the original work for its findings. Save a collection to share your selection of sources.